The generic name of Gwazi is Metformin Hydrochloride Extended-Release Tablets, and its action is mainly to reduce postprandial blood glucose. It is suitable for type 2 diabetes mellitus that is ineffective in the treatment of simple dietary control and physical exercise, especially obese type 2 diabetes mellitus, and can also be used in combination with insulin and sulfonylurea oral hypoglycemic drugs to synergize the control of blood glucose. The main mechanism of action of metformin is to increase the sensitivity of peripheral tissues to insulin, increase the utilization of glucose by non-insulin-dependent tissues, inhibit hepatic gluconeogenesis and thus reduce hepatic glucose output and inhibit glucose uptake by cells of the intestinal wall, etc., which can also lead to weight loss, and enteric-coated tablets can reduce the stimulation of the gastrointestinal tract by metformin. Adverse reactions are mainly gastrointestinal symptoms such as nausea and vomiting. Diarrhea and loss of appetite resolve spontaneously in most patients. It needs to be contraindicated in the presence of renal dysfunction caused by renal disease or other etiologies, congestive heart failure or other serious cardiopulmonary diseases requiring medication, severe infections, trauma, surgery, hypotension, metabolic acidosis, alcoholism, and allergy to the drug. If you need to take Metformin Hydrochloride Extended-Release Tablets, you need to follow the doctor’s instructions strictly and not take it privately.